[1,2,4]三唑[4,3-A]吡啶-3-硫醇 | 6952-68-7

• 物质功能分类: 化学试剂 - 有机试剂 - 硫醇盐
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: [1,2,4]三唑[4,3-A]吡啶-3-硫醇
• 中文别名: 1,2,4-三氮唑并[4,3-A]吡啶-3(2H)-硫酮；1,2,4-三唑[4,3-a]吡啶-3-硫醇
• 英文名称: [1,2,4]triazolo[4,3-a]pyridine-3-thiol
• 英文别名: s-Triazolo<4,3-a>pyridin-3-thiol；2H-[1,2,4]triazolo[4,3-a]pyridine-3-thione
• CAS: 6952-68-7
• 化学式: C₆H₅N₃S
• mdl: MFCD03783345
• 分子量: 151.192
• InChiKey: ZQMDNIPQCWNIMG-UHFFFAOYSA-N

物化性质

• 熔点：
  209-210℃
• 沸点：
  235.1±23.0℃ (760 Torr)
• 密度：
  1.49±0.1 g/cm3 (20 ºC 760 Torr)
• 闪点：
  96.0±22.6℃
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090
• 安全说明：
  S36/37
• 储存条件：
  存储条件：2-8°C，氮气环境下保存。

SDS

Name:	[1 2 4]Triazolo[4 3-a]pyridine-3-thiol 97% Material Safety Data Sheet
Synonym:
CAS:	6952-68-7

Section 1 - Chemical Product MSDS Name:[1 2 4]Triazolo[4 3-a]pyridine-3-thiol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6952-68-7	[1,2,4]Triazolo[4,3-a]pyridine-3-thiol	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6952-68-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5N3S
Molecular Weight: 151.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6952-68-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
[1,2,4]Triazolo[4,3-a]pyridine-3-thiol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 6952-68-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6952-68-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6952-68-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  [1,2,4]三唑[4,3-A]吡啶-3-硫醇 在 吡啶 、 tin(II) chloride dihdyrate 、 溶剂黄146 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 117.75h， 生成 N-[6-([1,2,4]triazolo[4,3-a]pyridin-3-ylsulphanyl)-1,3-benzothiazol-2-yl]cyclopropanecarboxamide
  参考文献：
  名称：

  NOVEL TRIAZOLO(4,3-A)PYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS

  摘要：

  本发明涉及公式（I）的新型产物：其中：Ra代表H、Hal、芳基或杂环芳基，可选地取代; Rb代表H、Rc、—COORc-CO-Rc或—CO—NRcRd; 其中Rc代表烷基、环烷基、杂环烷基、芳基和杂环芳基，均可选地取代; Rd代表H、烷基或环烷基; 这些产物以所有异构体形式和盐的形式作为药物，特别是作为MET抑制剂。

  公开号：

  US20110263594A1
• 作为产物：
  描述：

  2-溴吡啶 在 一水合肼 作用下， 反应 2.0h， 生成 [1,2,4]三唑[4,3-A]吡啶-3-硫醇
  参考文献：
  名称：

  The Synthesis of Some Substituted Thiocarbazones¹

  摘要：

  DOI：

  10.1021/ja01184a027

文献信息

• 类卢扎朵仑结构的芳胺基烷基硫类化合物及 其制备方法
  申请人：宜春学院

  公开号：CN105541702B

  公开（公告）日：2019-10-22

  一种类卢扎朵仑结构的芳胺基烷基硫类化合物及其制备方法，该化合物是将Ar1‑X1、通式Ⅲ所表示的化合物、Ar2‑X2及硫源加入到溶剂中，按反应式(1)加热反应完全后得到；或者是将Ar1‑X1、通式Ⅲ所表示的化合物及Ar2‑S‑M+加入到溶剂中，按反应式(2)加热反应完全后得到。本方法操作简单高效，反应条件温和，所用到的试剂廉价易得，安全性强，适于工业化大生产。
• [EN] QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉ DE QUINUCLIDINE COMME LIGANDS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011053292A1

  公开（公告）日：2011-05-05

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱7受体的配体，可能对治疗中枢神经系统的各种紊乱，特别是情感和神经退行性疾病有用。
• Novel aminoalkylthio derivatives of triazolopyridine or
  申请人：Centre D'Activite Et De Recherches Pharmaceutique Industrielle

  公开号：US04886805A1

  公开（公告）日：1989-12-12

  The present invention relates to novel compounds corresponding to the formula: ##STR1## in which: n represents an integer between 1 and 8 and optimally 2 or 3; (CH.sub.2).sub.n --N can also form a ring or a heterocycle, for example having 5 to 7 atoms and preferably 6 atoms; R.sub.1 and R.sub.2 can represent hydrogen or a lower alkyl having 1 to 5 carbon atoms or can form, together with the nitrogen, a ring such as pyrrolidine, piperidine, morpholine, thiomorpholine, phenyltetrahydropyridine, piperazine or piperazine N-substituted by an alkyl, a phenyl or a heterocycle; in the case of the phenyltetrahydropyridines and the phenylpiperazines or heteroarylpiperazines, the phenyl or the heterocycle may or may not be substituted by halogens or methoxy, thiomethyl, hydroxyl, nitro, amino, cyano, lower alkyl, trifluoromethyl or trichloromethyl groups; and R.sub.3, R.sub.4 and R.sub.5 can represent hydrogen, a lower alkyl, a hydroxyalkyl or hydroxybenzyl group, a halogen, a trifluoromethyl, a methoxy, a thiomethyl or a nitro or two of them can form a ring, in particular a phenyl in the case of the triazoloquinolines or the triazoloisoquinolines; and the non-toxic acid addition salts. These products are useful as drugs and possess analgesic properties, acting especially on the central nervous system as minor tranquilizers.

  本发明涉及通式为##STR1##的新颖化合物，其中：n代表1至8之间的整数，最优选2或3；(CH.sub.2).sub.n --N也可以形成环或杂环，例如具有5至7个原子，优选6个原子；R.sub.1和R.sub.2可以代表氢或具有1至5个碳原子的低级烷基，或者可以与氮一起形成环，如吡咯烷、哌啶、吗啉、硫代吗啉、苯并四氢吡啶、哌嗪或由烷基、苯基或杂环取代的哌嗪N；在苯并四氢吡啶和苯基哌嗪或杂环哌嗪的情况下，苯基或杂环可以被卤素、甲氧基、硫甲基、羟基、硝基、氨基、氰基、低级烷基、三氟甲基或三氯甲基取代或不取代；R.sub.3、R.sub.4和R.sub.5可以代表氢、低级烷基、羟基烷基或羟基苄基、卤素、三氟甲基、甲氧基、硫甲基或硝基，其中两个可以形成环，特别是在三唑并喹啉或三唑并异喹啉的情况下形成苯环；以及无毒的酸加成盐。这些产品作为药物有用，并具有镇痛特性，特别作用于中枢神经系统作为轻度镇静剂。
• [EN] cMET INHIBITORS<br/>[FR] INHIBITEURS DE CMET
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010019899A1

  公开（公告）日：2010-02-18

  Compounds of the following formula are provided for use with cMET: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  提供以下公式的化合物供与cMET一起使用：其中变量如本文所定义。还提供包含这些化合物的药物组合物、试剂盒和制造物品；用于制备这些化合物的有用中间体和方法；以及使用这些化合物的方法。
• X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells
  作者：Ling-Ling Yang、Hua-Li Wang、Lei Zhong、Chen Yuan、Si-Yu Liu、Zhu-Jun Yu、Sha Liu、Yu-Hang Yan、Chengyong Wu、Yuxi Wang、Zhouyu Wang、Yamei Yu、Qiang Chen、Guo-Bo Li

  DOI：10.1016/j.ejmech.2018.06.041

  日期：2018.7

  cancer. Selective small-molecule inhibitors for SIRT2 are sought as chemical tools and potential therapeutics. Here we report the X-ray crystal structure guided structure-activity relationship studies of new N-(3-(phenoxymethyl)phenyl)acetamide derivatives with SIRT2, which led to the identification of potent, selective SIRT2 inhibitors. Crystallographic analyses reveal that the new inhibitors act via

  人sirtuin 2（SIRT2）是烟酰胺腺嘌呤二核苷酸（NAD +）依赖性脱酰基酶，与人类疾病（包括癌症）有关。寻找用于SIRT2的选择性小分子抑制剂作为化学工具和潜在的治疗剂。在这里，我们报告了新的N-（3-（苯氧基甲基）苯基）乙酰胺衍生物与SIRT2的X射线晶体结构指导的结构-活性关系研究，从而鉴定了有效的，选择性的SIRT2抑制剂。晶体学分析表明，新的抑制剂通过诱导扩大的疏水口袋的形成，特别是模仿肉豆蔻酰化赖氨酸底物的相互作用而起作用。最有效的抑制剂24a可以剂量依赖性地提高非小细胞肺癌H441细胞中α-微管蛋白的乙酰化水平，该蛋白具有较高的SIRT2表达水平（通过Western印迹分析确定）。进一步的细胞分析表明，24a主要通过抑制细胞增殖而不是诱导细胞凋亡来抑制细胞生长。此外，24a可以抑制H441细胞的迁移和侵袭。这些结果为进一步开发新的有效，选择性和具有细胞活性的SIRT2